Last reviewed · How we verify
Azovan Blue (EVANS BLUE)
At a glance
| Generic name | EVANS BLUE |
|---|---|
| Sponsor | Pfizer |
| Target | Ectonucleotide pyrophosphatase/phosphodiesterase family member 2, Tyrosine-protein phosphatase non-receptor type 1, Luciferin 4-monooxygenase |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
Common side effects
Key clinical trials
- 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer (PHASE1,PHASE2)
- A Study to Evaluate the Safety and Efficacy of PRRT With 177Lu-EB-FAPI in Patients With Advanced Cholopancreatic Tumors (PHASE1)
- 68Ga-NOTA Evans Blue PET/CT in Patients With Lymphatic System Related Diseases (PHASE1)
- Clinical Translation of a Novel Albumin-Binding PET Radiotracer 68Ga-NEB (PHASE1)
- Effects of Tracheal Tube Size on Pulmonary Aspiration
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azovan Blue CI brief — competitive landscape report
- Azovan Blue updates RSS · CI watch RSS
- Pfizer portfolio CI